Safety of DRF and DMF in pediatric relapsing MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests the safety of two MS medicines (Diroximel Fumarate and Dimethyl Fumarate) in children with relapsing MS. The goal is to see how well they control relapses and what side effects may occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 10 to 17 years old (pediatric) with relapsing forms of multiple sclerosis.
- You must have had at least 1 relapse in the past year, or 2 relapses in the past 2 years, or an MRI showing active brain lesions in the past 6 months.
- You must have been free of any relapse for at least 30 days before starting the study.
- Your disability score (EDSS) must be between 0 and 5.0.
- You cannot have progressive MS, other conditions that mimic MS, certain cancers, or serious stomach/bowel problems.
- You must not be allergic to fumaric acid drugs or have had macular edema.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This study tests an oral capsule (dimethyl fumarate) to see how well it works for people with relapsing forms of MS. It may help reduce relapse frequency and slow disability progression.
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Hear when a new Relapsing Forms of Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.